SciSparc (OTCQB:SPRCY), formerly Therapix Biosciences, announced today that it closed a private placement worth $8.15 million. Tel Aviv, Israel-based SciSparc sold nearly 1.2 million units in the offering, with 916,316 units (consisting of 1 American Depositary Share, one Series A warrant to purchase an equal number of units purchased and one Series B warrant to […]
Therapix Biosciences
Therapix, Yissum ink nasal drug delivery pact
Therapix Biosciences (NSDQ:TRPX) said today that it inked a sublicense agreement for nasal drug delivery tech from Yissum Research Development Company at the Hebrew University. According to the deal, Yissum plans to give Therapix an exclusive, global, sub-licensable, royalty-bearing license for its nasal delivery tech to be used with cannabinoids. The technology was developed by […]
